{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:23:24Z","timestamp":1785414204580,"version":"3.56.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,23]]},"DOI":"10.7759\/cureus.28318","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T01:43:50Z","timestamp":1661305430000},"source":"Crossref","is-referenced-by-count":11,"title":["Clinical Utility of Mifepristone: Apprising the Expanding Horizons"],"prefix":"10.7759","author":[{"given":"Zalak V","family":"Karena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hetvee","family":"Vaghela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalp","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav K","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asjad R","family":"Chitalwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Mifepristone","author":"Autry BM","year":"2022","unstructured":"Autry BM, Wadhwa R. Mifepristone. StatPearls Publishing, Treasure Island, FL; 2022."},{"key":"ref2","article-title":"[The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy]","volume":"294","author":"Herrmann W","year":"1982","unstructured":"Herrmann W, Wyss R, Riondel A, Philibert D, Teutsch G, Sakiz E, Baulieu EE. [The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy]. C R Seances Acad Sci III. 1982, 294:933-8.","journal-title":"C R Seances Acad Sci III"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-720x.1992.tb01194.x","article-title":"RU 486 in France and England: corporate ethics and compulsory licensing","volume":"20","author":"Boland R","year":"1992","unstructured":"Boland R. RU 486 in France and England: corporate ethics and compulsory licensing. Law Med Health Care. 1992, 20:226-34. 10.1111\/j.1748-720x.1992.tb01194.x","journal-title":"Law Med Health Care"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/9.suppl_1.126","article-title":"RU486: the French experience","volume":"9","author":"Ulmann A","year":"1994","unstructured":"Ulmann A, Silvestre L. RU486: the French experience. Hum Reprod. 1994, 9:126-30. 10.1093\/humrep\/9.suppl_1.126","journal-title":"Hum Reprod"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/0028-2243(88)90089-5","article-title":"A novel approach to human fertility control: contragestion by the anti-progesterone RU 486","volume":"28","author":"Baulieu EE","year":"1988","unstructured":"Baulieu EE. A novel approach to human fertility control: contragestion by the anti-progesterone RU 486. Eur J Obstet Gynecol Reprod Biol. 1988, 28:125-9. 10.1016\/0028-2243(88)90089-5","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s0301-2115(01)00522-x","article-title":"Mifepristone: bioavailability, pharmacokinetics and use-effectiveness","volume":"101","author":"Sarkar NN","year":"2002","unstructured":"Sarkar NN. Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. Eur J Obstet Gynecol Reprod Biol. 2002, 101:113-20. 10.1016\/s0301-2115(01)00522-x","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.77.4.8408465","article-title":"The effects of an antiprogestin, mifepristone, and an antiestrogen, tamoxifen, on endometrial 17 beta-hydroxysteroid dehydrogenase and progestin and estrogen receptors during the luteal phase of the menstrual cycle: an immunohistochemical study","volume":"77","author":"M\u00e4entausta O","year":"1993","unstructured":"M\u00e4entausta O, Svalander P, Danielsson KG, Bygdeman M, Vihko R. The effects of an antiprogestin, mifepristone, and an antiestrogen, tamoxifen, on endometrial 17 beta-hydroxysteroid dehydrogenase and progestin and estrogen receptors during the luteal phase of the menstrual cycle: an immunohistochemical study. J Clin Endocrinol Metab. 1993, 77:913-8. 10.1210\/jcem.77.4.8408465","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-1242-0_21","article-title":"Pharmacokinetic and clinical studies of RU 486 for fertility regulation","author":"Swahn ML","year":"1985","unstructured":"Swahn ML. Pharmacokinetic and clinical studies of RU 486 for fertility regulation. Reproductive Biology. Baulieu EE  (ed): Springer, Boston, MA; 1985. 249-58. 10.1007\/978-1-4684-1242-0_21"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(85)90115-5","article-title":"Progesterone receptor blockage. Effect on uterine contractility and early pregnancy","volume":"32","author":"Bygdeman M","year":"1985","unstructured":"Bygdeman M, Swahn ML. Progesterone receptor blockage. Effect on uterine contractility and early pregnancy. Contraception. 1985, 32:45-51. 10.1016\/0010-7824(85)90115-5","journal-title":"Contraception"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000001688","article-title":"Simultaneous administration compared with a 24-hour mifepristone-misoprostol interval in second-trimester abortion: a randomized controlled trial","volume":"128","author":"Abbas DF","year":"2016","unstructured":"Abbas DF, Blum J, Ngoc NT, Nga NT, Chi HT, Martin R, Winikoff B. Simultaneous administration compared with a 24-hour mifepristone-misoprostol interval in second-trimester abortion: a randomized controlled trial. Obstet Gynecol. 2016, 128:1077-83. 10.1097\/AOG.0000000000001688","journal-title":"Obstet Gynecol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2018.11.002","article-title":"Medical abortion in the late first trimester: a systematic review","volume":"99","author":"Kapp N","year":"2019","unstructured":"Kapp N, Eckersberger E, Lavelanet A, Rodriguez MI. Medical abortion in the late first trimester: a systematic review. Contraception. 2019, 99:77-86. 10.1016\/j.contraception.2018.11.002","journal-title":"Contraception"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2015.06.001","article-title":"Continuing pregnancy after mifepristone and \"reversal\" of first-trimester medical abortion: a systematic review","volume":"92","author":"Grossman D","year":"2015","unstructured":"Grossman D, White K, Harris L, Reeves M, Blumenthal PD, Winikoff B, Grimes DA. Continuing pregnancy after mifepristone and \"reversal\" of first-trimester medical abortion: a systematic review. Contraception. 2015, 92:206-11. 10.1016\/j.contraception.2015.06.001","journal-title":"Contraception"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2019.05.006","article-title":"Current and potential methods for second trimester abortion","volume":"63","author":"Lerma K","year":"2020","unstructured":"Lerma K, Blumenthal PD. Current and potential methods for second trimester abortion. Best Pract Res Clin Obstet Gynaecol. 2020, 63:24-36. 10.1016\/j.bpobgyn.2019.05.006","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3182a2dcb7","article-title":"Mifepristone followed by misoprostol or oxytocin for second-trimester abortion: a randomized controlled trial","volume":"122","author":"Elami-Suzin M","year":"2013","unstructured":"Elami-Suzin M, Freeman MD, Porat N, Rojansky N, Laufer N, Ben-Meir A. Mifepristone followed by misoprostol or oxytocin for second-trimester abortion: a randomized controlled trial. Obstet Gynecol. 2013, 122:815-20. 10.1097\/AOG.0b013e3182a2dcb7","journal-title":"Obstet Gynecol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/14767050802283027","article-title":"Mifepristone and misoprostol versus Dilapan and sulprostone for second trimester termination of pregnancy","volume":"21","author":"Jansen NE","year":"2008","unstructured":"Jansen NE, Pasker-De Jong PC, Zondervan HA. Mifepristone and misoprostol versus Dilapan and sulprostone for second trimester termination of pregnancy. J Matern Fetal Neonatal Med. 2008, 21:847-51. 10.1080\/14767050802283027","journal-title":"J Matern Fetal Neonatal Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31788-8","article-title":"Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (MifeMiso): a randomised, double-blind, placebo-controlled trial","volume":"396","author":"Chu JJ","year":"2020","unstructured":"Chu JJ, Devall AJ, Beeson LE, et al.. Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (MifeMiso): a randomised, double-blind, placebo-controlled trial. Lancet. 2020, 396:770-8. 10.1016\/S0140-6736(20)31788-8","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.16737","article-title":"Cost-effectiveness of mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage: an economic evaluation based on the MifeMiso trial","volume":"128","author":"Okeke Ogwulu CB","year":"2021","unstructured":"Okeke Ogwulu CB, Williams EV, Chu JJ, et al.. Cost-effectiveness of mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage: an economic evaluation based on the MifeMiso trial. BJOG. 2021, 128:1534-45. 10.1111\/1471-0528.16737","journal-title":"BJOG"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3310\/hta25680","article-title":"Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT","volume":"25","author":"Devall A","year":"2021","unstructured":"Devall A, Chu J, Beeson L, et al.. Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT. Health Technol Assess. 2021, 25:1-114. 10.3310\/hta25680","journal-title":"Health Technol Assess"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(90)91193-g","article-title":"Induction of labor with mifepristone (RU 486) in intrauterine fetal death","volume":"163","author":"Cabrol D","year":"1990","unstructured":"Cabrol D, Dubois C, Cronje H, et al.. Induction of labor with mifepristone (RU 486) in intrauterine fetal death. Am J Obstet Gynecol. 1990, 163:540-2. 10.1016\/0002-9378(90)91193-g","journal-title":"Am J Obstet Gynecol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004344","article-title":"Pretreatment with mifepristone compared with misoprostol alone for delivery after fetal death between 14 and 28 weeks of gestation: a randomized controlled trial","volume":"137","author":"Allanson ER","year":"2021","unstructured":"Allanson ER, Copson S, Spilsbury K, et al.. Pretreatment with mifepristone compared with misoprostol alone for delivery after fetal death between 14 and 28 weeks of gestation: a randomized controlled trial. Obstet Gynecol. 2021, 137:801-9. 10.1097\/AOG.0000000000004344","journal-title":"Obstet Gynecol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/jog.12815","article-title":"Mifepristone and misoprostol compared with misoprostol alone for induction of labor in intrauterine fetal death: a randomized trial","volume":"41","author":"Chaudhuri P","year":"2015","unstructured":"Chaudhuri P, Datta S. Mifepristone and misoprostol compared with misoprostol alone for induction of labor in intrauterine fetal death: a randomized trial. J Obstet Gynaecol Res. 2015, 41:1884-90. 10.1111\/jog.12815","journal-title":"J Obstet Gynaecol Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(92)90126-e","article-title":"A randomized clinical trial of mifepristone (RU486) for induction of delayed menses: efficacy and acceptability","volume":"46","author":"Grimes DA","year":"1992","unstructured":"Grimes DA, Mishell DR Jr, David HP. A randomized clinical trial of mifepristone (RU486) for induction of delayed menses: efficacy and acceptability. Contraception. 1992, 46:1-10. 10.1016\/0010-7824(92)90126-e","journal-title":"Contraception"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/s0010-7824(03)00148-3","article-title":"The possibility of using mifepristone for menstrual induction","volume":"68","author":"Bygdeman M","year":"2003","unstructured":"Bygdeman M. The possibility of using mifepristone for menstrual induction. Contraception. 2003, 68:495-8. 10.1016\/s0010-7824(03)00148-3","journal-title":"Contraception"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2003.09.009","article-title":"Menstrual induction with mifepristone and misoprostol","volume":"68","author":"Xiao B","year":"2003","unstructured":"Xiao B, von Hertzen H, Zhao H, Piaggio G. Menstrual induction with mifepristone and misoprostol. Contraception. 2003, 68:489-94. 10.1016\/j.contraception.2003.09.009","journal-title":"Contraception"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/s0029-7844(02)02006-9","article-title":"Emergency contraception with mifepristone and levonorgestrel: mechanism of action","volume":"100","author":"Marions L","year":"2002","unstructured":"Marions L, Hultenby K, Lindell I, Sun X, St\u00e5bi B, Gemzell Danielsson K. Emergency contraception with mifepristone and levonorgestrel: mechanism of action. Obstet Gynecol. 2002, 100:65-71. 10.1016\/s0029-7844(02)02006-9","journal-title":"Obstet Gynecol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3109\/13625189909064011","article-title":"Contraceptive use of antiprogestin","volume":"4","author":"Bygdeman M","year":"1999","unstructured":"Bygdeman M, Danielsson KG, Marions L, Swahn ML. Contraceptive use of antiprogestin. Eur J Contracept Reprod Health Care. 1999, 4:103-7. 10.3109\/13625189909064011","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.humrep.a136809","article-title":"The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium","volume":"3","author":"Swahn ML","year":"1988","unstructured":"Swahn ML, Johannisson E, Daniore V, de la Torre B, Bygdeman M. The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium. Hum Reprod. 1988, 3:915-21. 10.1093\/oxfordjournals.humrep.a136809","journal-title":"Hum Reprod"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-65-6-1135","article-title":"Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486","volume":"65","author":"Liu JH","year":"1987","unstructured":"Liu JH, Garzo G, Morris S, Stuenkel C, Ulmann A, Yen SS. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486. J Clin Endocrinol Metab. 1987, 65:1135-40. 10.1210\/jcem-65-6-1135","journal-title":"J Clin Endocrinol Metab"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001324.pub5","article-title":"Interventions for emergency contraception","volume":"8","author":"Shen J","year":"2017","unstructured":"Shen J, Che Y, Showell E, Chen K, Cheng L. Interventions for emergency contraception. Cochrane Database Syst Rev. 2017, 8:CD001324. 10.1002\/14651858.CD001324.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2003.07.002","article-title":"Mifepristone: a novel estrogen-free daily contraceptive pill","volume":"68","author":"Baird DT","year":"2003","unstructured":"Baird DT, Brown A, Cheng L, Critchley HO, Lin S, Narvekar N, Williams AR. Mifepristone: a novel estrogen-free daily contraceptive pill. Steroids. 2003, 68:1099-105. 10.1016\/j.steroids.2003.07.002","journal-title":"Steroids"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/9.suppl_1.69","article-title":"Effect of mifepristone on inhibition of ovulation and induction of luteolysis","volume":"9","author":"Spitz IM","year":"1994","unstructured":"Spitz IM, Croxatto HB, L\u00e4hteenm\u00e4ki P, Heikinheimo O, Bardin CW. Effect of mifepristone on inhibition of ovulation and induction of luteolysis. Hum Reprod. 1994, 9:69-76. 10.1093\/humrep\/9.suppl_1.69","journal-title":"Hum Reprod"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.74.3.1740491","article-title":"Evidence for a critical role of progesterone in the regulation of the midcycle gonadotropin surge and ovulation","volume":"74","author":"Batista MC","year":"1992","unstructured":"Batista MC, Cartledge TP, Zellmer AW, Nieman LK, Merriam GR, Loriaux DL. Evidence for a critical role of progesterone in the regulation of the midcycle gonadotropin surge and ovulation. J Clin Endocrinol Metab. 1992, 74:565-70. 10.1210\/jcem.74.3.1740491","journal-title":"J Clin Endocrinol Metab"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.humrep.a137776","article-title":"Inhibition of ovulation by low-dose mifepristone (RU 486)","volume":"7","author":"Ledger WL","year":"1992","unstructured":"Ledger WL, Sweeting VM, Hillier H, Baird DT. Inhibition of ovulation by low-dose mifepristone (RU 486). Hum Reprod. 1992, 7:945-50. 10.1093\/oxfordjournals.humrep.a137776","journal-title":"Hum Reprod"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)53478-5","article-title":"Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin","volume":"53","author":"Kekkonen R","year":"1990","unstructured":"Kekkonen R, Alfthan H, Haukkamaa M, Heikinheimo O, Luukkainen T, L\u00e4hteenm\u00e4ki P. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin. Fertil Steril. 1990, 53:747-50. 10.1016\/S0015-0282(16)53478-5","journal-title":"Fertil Steril"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2008.09.005","article-title":"Evaluation of mifepristone as a once a month contraceptive pill","volume":"200","author":"Agarwal M","year":"2009","unstructured":"Agarwal M, Das V, Agarwal A, Pandey A, Srivastava D. Evaluation of mifepristone as a once a month contraceptive pill. Am J Obstet Gynecol. 2009, 200:e27-9. 10.1016\/j.ajog.2008.09.005","journal-title":"Am J Obstet Gynecol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2006.08.013","article-title":"Weekly contraception with mifepristone","volume":"75","author":"Pei K","year":"2007","unstructured":"Pei K, Xiao B, Jing X, Lu S, Wei L, Zhao H. Weekly contraception with mifepristone. Contraception. 2007, 75:40-4. 10.1016\/j.contraception.2006.08.013","journal-title":"Contraception"},{"key":"ref37","article-title":"[The role of the progesterone antagonist, RU 486 (mifepristone), in preoperative cervical dilatation during the luteal phase. A randomized double-blind study]","volume":"18","author":"Fernandez H","year":"1990","unstructured":"Fernandez H, Durlot F, Dubois C, Ulmann A, Frydman R. [The role of the progesterone antagonist, RU 486 (mifepristone), in preoperative cervical dilatation during the luteal phase. A randomized double-blind study]. Contracept Fertil Sex (Paris). 1990, 18:41-3.","journal-title":"Contracept Fertil Sex (Paris)"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh420","article-title":"Mifepristone does not induce cervical softening in non-pregnant women","volume":"19","author":"Ben-Chetrit A","year":"2004","unstructured":"Ben-Chetrit A, Eldar-Geva T, Lindenberg T, et al.. Mifepristone does not induce cervical softening in non-pregnant women. Hum Reprod. 2004, 19:2372-6. 10.1093\/humrep\/deh420","journal-title":"Hum Reprod"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91303-r","article-title":"Effect of mifepristone on dilatation of the pregnant and non-pregnant cervix","volume":"335","author":"Gupta JK","year":"1990","unstructured":"Gupta JK, Johnson N. Effect of mifepristone on dilatation of the pregnant and non-pregnant cervix. Lancet. 1990, 335:1238-40. 10.1016\/0140-6736(90)91303-r","journal-title":"Lancet"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)93421-5","article-title":"Mifepristone for induction of labour","volume":"337","author":"Frydman R","year":"1991","unstructured":"Frydman R, Baton C, Lelaidier C, Vial M, Bourget P, Fernandez H. Mifepristone for induction of labour. Lancet. 1991, 337:488-9. 10.1016\/0140-6736(91)93421-5","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2017.08.038","article-title":"Outcomes of mifepristone usage for cervical ripening and induction of labour in full-term pregnancy. Randomized controlled trial","volume":"217","author":"Baev OR","year":"2017","unstructured":"Baev OR, Rumyantseva VP, Tysyachnyu OV, Kozlova OA, Sukhikh GT. Outcomes of mifepristone usage for cervical ripening and induction of labour in full-term pregnancy. Randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2017, 217:144-9. 10.1016\/j.ejogrb.2017.08.038","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002865.pub2","article-title":"Mifepristone for induction of labour","author":"Hapangama D","year":"2009","unstructured":"Hapangama D, Neilson JP. Mifepristone for induction of labour. Cochrane Database Syst Rev. 2009, CD002865. 10.1002\/14651858.CD002865.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref43","article-title":"[Combined use of methotrexate and mifepristone for ectopic pregnancy management: a meta-analysis]","volume":"26","author":"Song HD","year":"2006","unstructured":"Song HD, Chen SL, He JX, Qiu YW. [Combined use of methotrexate and mifepristone for ectopic pregnancy management: a meta-analysis]. Nan Fang Yi Ke Da Xue Xue Bao. 2006, 26:1815-7.","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9378(98)70057-2","article-title":"Treating ectopic pregnancy with the combination of mifepristone and methotrexate: a phase II nonrandomized study","volume":"179","author":"Perdu M","year":"1998","unstructured":"Perdu M, Camus E, Rozenberg P, Goffinet F, Chastang C, Philippe HJ, Nisand I. Treating ectopic pregnancy with the combination of mifepristone and methotrexate: a phase II nonrandomized study. Am J Obstet Gynecol. 1998, 179:640-3. 10.1016\/s0002-9378(98)70057-2","journal-title":"Am J Obstet Gynecol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deg344","article-title":"Medical treatment of ectopic pregnancies: a randomized clinical trial comparing methotrexate-mifepristone and methotrexate-placebo","volume":"18","author":"Rozenberg P","year":"2003","unstructured":"Rozenberg P, Chevret S, Camus E, et al.. Medical treatment of ectopic pregnancies: a randomized clinical trial comparing methotrexate-mifepristone and methotrexate-placebo. Hum Reprod. 2003, 18:1802-8. 10.1093\/humrep\/deg344","journal-title":"Hum Reprod"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9378(98)70316-3","article-title":"Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486)","volume":"178","author":"Kettel LM","year":"1998","unstructured":"Kettel LM, Murphy AA, Morales AJ, Yen SS. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol. 1998, 178:1151-6. 10.1016\/s0002-9378(98)70316-3","journal-title":"Am J Obstet Gynecol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/s0015-0282(16)58022-4","article-title":"Treatment of endometriosis with the antiprogesterone mifepristone (RU486)","volume":"65","author":"Kettel LM","year":"1996","unstructured":"Kettel LM, Murphy AA, Morales AJ, Ulmann A, Baulieu EE, Yen SS. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril. 1996, 65:23-8. 10.1016\/s0015-0282(16)58022-4","journal-title":"Fertil Steril"},{"key":"ref48","doi-asserted-by":"crossref","DOI":"10.12891\/ceog2086.2016","article-title":"Effect of mifepristone in the different treatments of endometriosis","volume":"43","author":"Zhang YX","year":"2016","unstructured":"Zhang YX. Effect of mifepristone in the different treatments of endometriosis. Clin Exp Obstet Gynecol. 2016, 43:350-3.","journal-title":"Clin Exp Obstet Gynecol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-1225","article-title":"Progesterone is essential for maintenance and growth of uterine leiomyoma","volume":"151","author":"Ishikawa H","year":"2010","unstructured":"Ishikawa H, Ishi K, Serna VA, Kakazu R, Bulun SE, Kurita T. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology. 2010, 151:2433-42. 10.1210\/en.2009-1225","journal-title":"Endocrinology"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0725","article-title":"Progesterone receptor regulates Bcl-2 gene expression through direct binding to its promoter region in uterine leiomyoma cells","volume":"92","author":"Yin P","year":"2007","unstructured":"Yin P, Lin Z, Cheng YH, et al.. Progesterone receptor regulates Bcl-2 gene expression through direct binding to its promoter region in uterine leiomyoma cells. J Clin Endocrinol Metab. 2007, 92:4459-66. 10.1210\/jc.2007-0725","journal-title":"J Clin Endocrinol Metab"},{"key":"ref51","article-title":"[A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone]","volume":"33","author":"Zeng C","year":"1998","unstructured":"Zeng C, Gu M, Huang H. [A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone]. Zhonghua Fu Chan Ke Za Zhi. 1998, 33:490-2.","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/del182","article-title":"Mifepristone-induced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decrease in stromal vascular endothelial growth factor","volume":"21","author":"Narvekar N","year":"2006","unstructured":"Narvekar N, Critchley HO, Cheng L, Baird DT. Mifepristone-induced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decrease in stromal vascular endothelial growth factor. Hum Reprod. 2006, 21:2312-8. 10.1093\/humrep\/del182","journal-title":"Hum Reprod"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2009.12.012","article-title":"Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century","volume":"82","author":"Spitz IM","year":"2010","unstructured":"Spitz IM. Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century. Contraception. 2010, 82:442-52. 10.1016\/j.contraception.2009.12.012","journal-title":"Contraception"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007687.pub2","article-title":"Mifepristone for uterine fibroids","author":"Tristan M","year":"2012","unstructured":"Tristan M, Orozco LJ, Steed A, Ram\u00edrez-Morera A, Stone P. Mifepristone for uterine fibroids. Cochrane Database Syst Rev. 2012, CD007687. 10.1002\/14651858.CD007687.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref55","article-title":"Low dose mifepristone in medical management of uterine leiomyoma - an experience from a tertiary care hospital from north India","volume":"137","author":"Kulshrestha V","year":"2013","unstructured":"Kulshrestha V, Kriplani A, Agarwal N, Sareen N, Garg P, Hari S, Thulkar J. Low dose mifepristone in medical management of uterine leiomyoma - an experience from a tertiary care hospital from north India. Indian J Med Res. 2013, 137:1154-62.","journal-title":"Indian J Med Res"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.76.2.8432797","article-title":"Regression of uterine leiomyomata in response to the antiprogesterone RU 486","volume":"76","author":"Murphy AA","year":"1993","unstructured":"Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SS. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab. 1993, 76:513-7. 10.1210\/jcem.76.2.8432797","journal-title":"J Clin Endocrinol Metab"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000127622.63269.8b","article-title":"Systematic review of mifepristone for the treatment of uterine leiomyomata","volume":"103","author":"Steinauer J","year":"2004","unstructured":"Steinauer J, Pritts EA, Jackson R, Jacoby AF. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol. 2004, 103:1331-6. 10.1097\/01.AOG.0000127622.63269.8b","journal-title":"Obstet Gynecol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14866","article-title":"A new trick for an old dog: the application of mifepristone in the treatment of adenomyosis","volume":"24","author":"Che X","year":"2020","unstructured":"Che X, Wang J, He J, et al.. A new trick for an old dog: the application of mifepristone in the treatment of adenomyosis. J Cell Mol Med. 2020, 24:1724-37. 10.1111\/jcmm.14866","journal-title":"J Cell Mol Med"},{"key":"ref59","doi-asserted-by":"crossref","DOI":"10.12891\/ceog15872014","article-title":"The influence of mifepristone to caspase 3 expression in adenomyosis","volume":"41","author":"Wang Y","year":"2014","unstructured":"Wang Y, Jiang X, Wang S. The influence of mifepristone to caspase 3 expression in adenomyosis. Clin Exp Obstet Gynecol. 2014, 41:154-7.","journal-title":"Clin Exp Obstet Gynecol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.39252","article-title":"The new application of mifepristone in the relief of adenomyosis-caused dysmenorrhea","volume":"17","author":"Che X","year":"2020","unstructured":"Che X, Wang J, He J, Guo X, Li T, Zhang X. The new application of mifepristone in the relief of adenomyosis-caused dysmenorrhea. Int J Med Sci. 2020, 17:224-33. 10.7150\/ijms.39252","journal-title":"Int J Med Sci"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/s0039-128x(03)00132-6","article-title":"Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate","volume":"68","author":"Jain JK","year":"2003","unstructured":"Jain JK, Nicosia AF, Nucatola DL, Lu JJ, Kuo J, Felix JC. Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate. Steroids. 2003, 68:1115-9. 10.1016\/s0039-128x(03)00132-6","journal-title":"Steroids"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dei383","article-title":"Effects of mifepristone on proliferation and apoptosis of human endometrium in new users of medroxyprogesterone acetate","volume":"21","author":"Jain JK","year":"2006","unstructured":"Jain JK, Li A, Yang W, Minoo P, Felix JC. Effects of mifepristone on proliferation and apoptosis of human endometrium in new users of medroxyprogesterone acetate. Hum Reprod. 2006, 21:798-809. 10.1093\/humrep\/dei383","journal-title":"Hum Reprod"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2010.01.015","article-title":"Efficacy of mifepristone in reducing intermenstrual vaginal bleeding in users of the levonorgestrel intrauterine system","volume":"109","author":"Lal S","year":"2010","unstructured":"Lal S, Kriplani A, Kulshrestha V, Sharma M, Agarwal N. Efficacy of mifepristone in reducing intermenstrual vaginal bleeding in users of the levonorgestrel intrauterine system. Int J Gynaecol Obstet. 2010, 109:128-30. 10.1016\/j.ijgo.2010.01.015","journal-title":"Int J Gynaecol Obstet"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dey296","article-title":"Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial","volume":"33","author":"Papaikonomou K","year":"2018","unstructured":"Papaikonomou K, Kopp Kallner H, S\u00f6derdahl F, Gemzell-Danielsson K. Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Hum Reprod. 2018, 33:2002-9. 10.1093\/humrep\/dey296","journal-title":"Hum Reprod"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1080\/13625180500539505","article-title":"Effects of a preovulatory single low dose of mifepristone on ovarian function","volume":"11","author":"van der Stege JG","year":"2006","unstructured":"van der Stege JG, Pahl-van Beest EH, Beerthuizen RJ, van Lunsen RH, Scholten PC, Bogchelman DH. Effects of a preovulatory single low dose of mifepristone on ovarian function. Eur J Contracept Reprod Health Care. 2006, 11:104-8. 10.1080\/13625180500539505","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(97)81918-8","article-title":"Potential enhancement of endometrial receptivity in cycles using controlled ovarian hyperstimulation with antiprogestins: a hypothesis","volume":"67","author":"Paulson RJ","year":"1997","unstructured":"Paulson RJ, Sauer MV, Lobo RA. Potential enhancement of endometrial receptivity in cycles using controlled ovarian hyperstimulation with antiprogestins: a hypothesis. Fertil Steril. 1997, 67:321-5. 10.1016\/S0015-0282(97)81918-8","journal-title":"Fertil Steril"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1160","article-title":"Mifepristone is an effective oral alternative for the prevention of premature luteinizing hormone surges and\/or premature luteinization in women undergoing controlled ovarian hyperstimulation for in vitro fertilization","volume":"90","author":"Escudero EL","year":"2005","unstructured":"Escudero EL, Boerrigter PJ, Bennink HJ, et al.. Mifepristone is an effective oral alternative for the prevention of premature luteinizing hormone surges and\/or premature luteinization in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab. 2005, 90:2081-8. 10.1210\/jc.2004-1160","journal-title":"J Clin Endocrinol Metab"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1202","article-title":"Mifepristone for management of Cushing's syndrome","volume":"33","author":"Morgan FH","year":"2013","unstructured":"Morgan FH, Laufgraben MJ. Mifepristone for management of Cushing's syndrome. Pharmacotherapy. 2013, 33:319-29. 10.1002\/phar.1202","journal-title":"Pharmacotherapy"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome","volume":"97","author":"Fleseriu M","year":"2012","unstructured":"Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012, 97:2039-49. 10.1210\/jc.2011-3350","journal-title":"J Clin Endocrinol Metab"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12332","article-title":"Global clinical response in Cushing's syndrome patients treated with mifepristone","volume":"80","author":"Katznelson L","year":"2014","unstructured":"Katznelson L, Loriaux DL, Feldman D, Braunstein GD, Schteingart DE, Gross C. Global clinical response in Cushing's syndrome patients treated with mifepristone. Clin Endocrinol (Oxf). 2014, 80:562-9. 10.1111\/cen.12332","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-020-00105-4","article-title":"Clinical management of patients with Cushing syndrome treated with mifepristone: consensus recommendations","volume":"6","author":"Brown DR","year":"2020","unstructured":"Brown DR, East HE, Eilerman BS, et al.. Clinical management of patients with Cushing syndrome treated with mifepristone: consensus recommendations. Clin Diabetes Endocrinol. 2020, 6:18. 10.1186\/s40842-020-00105-4","journal-title":"Clin Diabetes Endocrinol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab046","article-title":"Mifepristone improves adipose tissue insulin sensitivity in insulin resistant individuals","volume":"106","author":"Gubbi S","year":"2021","unstructured":"Gubbi S, Muniyappa R, Sharma ST, Grewal S, McGlotten R, Nieman LK. Mifepristone improves adipose tissue insulin sensitivity in insulin resistant individuals. J Clin Endocrinol Metab. 2021, 106:1501-15. 10.1210\/clinem\/dgab046","journal-title":"J Clin Endocrinol Metab"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-016-2457-1","article-title":"A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer","volume":"5","author":"Nanda R","year":"2016","unstructured":"Nanda R, Stringer-Reasor EM, Saha P, et al.. A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer. Springerplus. 2016, 5:947. 10.1186\/s40064-016-2457-1","journal-title":"Springerplus"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.39491","article-title":"Mifepristone derivative FZU-00,003 suppresses triple-negative breast cancer cell growth partially via miR-153-KLF5 axis","volume":"16","author":"Liu R","year":"2020","unstructured":"Liu R, Chen H, Zhao P, et al.. Mifepristone derivative FZU-00,003 suppresses triple-negative breast cancer cell growth partially via miR-153-KLF5 axis. Int J Biol Sci. 2020, 16:611-9. 10.7150\/ijbs.39491","journal-title":"Int J Biol Sci"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2013595117","article-title":"Targeting progesterone signaling prevents metastatic ovarian cancer","volume":"117","author":"Kim O","year":"2020","unstructured":"Kim O, Park EY, Kwon SY, et al.. Targeting progesterone signaling prevents metastatic ovarian cancer. Proc Natl Acad Sci U S A. 2020, 117:31993-2004. 10.1073\/pnas.2013595117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0164","article-title":"Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo","volume":"13","author":"Goyeneche AA","year":"2007","unstructured":"Goyeneche AA, Car\u00f3n RW, Telleria CM. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin Cancer Res. 2007, 13:3370-9. 10.1158\/1078-0432.CCR-07-0164","journal-title":"Clin Cancer Res"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4049","article-title":"Phase I\/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer","volume":"28","author":"Serritella AV","year":"2022","unstructured":"Serritella AV, Shevrin D, Heath EI, et al.. Phase I\/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2022, 28:1549-59. 10.1158\/1078-0432.CCR-21-4049","journal-title":"Clin Cancer Res"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1080\/07357900601062339","article-title":"Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma","volume":"24","author":"Grunberg SM","year":"2006","unstructured":"Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 2006, 24:727-33. 10.1080\/07357900601062339","journal-title":"Cancer Invest"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2005.05.056","article-title":"Management of patients receiving long-term treatment with mifepristone","volume":"84","author":"Spitz IM","year":"2005","unstructured":"Spitz IM, Grunberg SM, Chabbert-Buffet N, Lindenberg T, Gelber H, Sitruk-Ware R. Management of patients receiving long-term treatment with mifepristone. Fertil Steril. 2005, 84:1719-26. 10.1016\/j.fertnstert.2005.05.056","journal-title":"Fertil Steril"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.606907","article-title":"Mifepristone repurposing in treatment of high-grade gliomas","volume":"11","author":"Llaguno-Munive M","year":"2021","unstructured":"Llaguno-Munive M, Vazquez-Lopez MI, Jurado R, Garcia-Lopez P. Mifepristone repurposing in treatment of high-grade gliomas. Front Oncol. 2021, 11:606907. 10.3389\/fonc.2021.606907","journal-title":"Front Oncol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.6490","article-title":"Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005","volume":"33","author":"Ji Y","year":"2015","unstructured":"Ji Y, Rankin C, Grunberg S, et al.. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015, 33:4093-8. 10.1200\/JCO.2015.61.6490","journal-title":"J Clin Oncol"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1987.66.4.0584","article-title":"Effect of the antiprogesterone RU-38486 on meningioma implanted into nude mice","volume":"66","author":"Olson JJ","year":"1987","unstructured":"Olson JJ, Beck DW, Schlechte JA, Loh PM. Effect of the antiprogesterone RU-38486 on meningioma implanted into nude mice. J Neurosurg. 1987, 66:584-7. 10.3171\/jns.1987.66.4.0584","journal-title":"J Neurosurg"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11010016","article-title":"Mifepristone overcomes tumor resistance to temozolomide associated with DNA damage repair and apoptosis in an orthotopic model of glioblastoma","volume":"11","author":"Llaguno-Munive M","year":"2018","unstructured":"Llaguno-Munive M, Romero-Pi\u00f1a M, Serrano-Bello J, et al.. Mifepristone overcomes tumor resistance to temozolomide associated with DNA damage repair and apoptosis in an orthotopic model of glioblastoma. Cancers (Basel). 2018, 11:16. 10.3390\/cancers11010016","journal-title":"Cancers (Basel)"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02306-y","article-title":"Anticancer effects of mifepristone on human uveal melanoma cells","volume":"21","author":"Alvarez PB","year":"2021","unstructured":"Alvarez PB, Laskaris A, Goyeneche AA, Chen Y, Telleria CM, Burnier JV. Anticancer effects of mifepristone on human uveal melanoma cells. Cancer Cell Int. 2021, 21:607. 10.1186\/s12935-021-02306-y","journal-title":"Cancer Cell Int"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.4321\/s0365-66912009001000003","article-title":"[New developments in glaucoma medical treatment]","volume":"84","author":"Mu\u00f1oz-Negrete FJ","year":"2009","unstructured":"Mu\u00f1oz-Negrete FJ, P\u00e9rez-L\u00f3pez M, Won Kim HR, Rebolleda G. [New developments in glaucoma medical treatment]. Arch Soc Esp Oftalmol. 2009, 84:491-500. 10.4321\/s0365-66912009001000003","journal-title":"Arch Soc Esp Oftalmol"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.3109\/02713688908997574","article-title":"Interaction between progesterone and mifepristone on intraocular pressure in rabbits","volume":"8","author":"Green K","year":"1989","unstructured":"Green K, Cheeks L, Slagle T, Phillips CI. Interaction between progesterone and mifepristone on intraocular pressure in rabbits. Curr Eye Res. 1989, 8:317-20. 10.3109\/02713688908997574","journal-title":"Curr Eye Res"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1159\/000267030","article-title":"Effects of mifepristone on rabbit intraocular pressure in the presence and absence of dexamethasone","volume":"22","author":"Green K","year":"1990","unstructured":"Green K, Cheeks L, Slagle T, Phillips CI. Effects of mifepristone on rabbit intraocular pressure in the presence and absence of dexamethasone. Ophthalmic Res. 1990, 22:247-52. 10.1159\/000267030","journal-title":"Ophthalmic Res"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300884","article-title":"Clinical and biological effects of mifepristone treatment for psychotic depression","volume":"31","author":"Flores BH","year":"2006","unstructured":"Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology. 2006, 31:628-36. 10.1038\/sj.npp.1300884","journal-title":"Neuropsychopharmacology"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105610","article-title":"Alcohol dependence and withdrawal increase sensitivity of central amygdalar GABAergic synapses to the glucocorticoid receptor antagonist mifepristone in male rats","volume":"164","author":"Khom S","year":"2022","unstructured":"Khom S, Rodriguez L, Gandhi P, et al.. Alcohol dependence and withdrawal increase sensitivity of central amygdalar GABAergic synapses to the glucocorticoid receptor antagonist mifepristone in male rats. Neurobiol Dis. 2022, 164:105610. 10.1016\/j.nbd.2022.105610","journal-title":"Neurobiol Dis"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2006.03.039","article-title":"The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats","volume":"171","author":"Beebe KL","year":"2006","unstructured":"Beebe KL, Block T, Debattista C, Blasey C, Belanoff JK. The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats. Behav Brain Res. 2006, 171:225-9. 10.1016\/j.bbr.2006.03.039","journal-title":"Behav Brain Res"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-015-0059-5","article-title":"Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extension","volume":"15","author":"Fein HG","year":"2015","unstructured":"Fein HG, Vaughan TB 3rd, Kushner H, Cram D, Nguyen D. Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extension. BMC Endocr Disord. 2015, 15:63. 10.1186\/s12902-015-0059-5","journal-title":"BMC Endocr Disord"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.3928\/02793695-20130513-01","article-title":"Mifepristone as a therapeutic agent in psychiatry","volume":"51","author":"Howland RH","year":"2013","unstructured":"Howland RH. Mifepristone as a therapeutic agent in psychiatry. J Psychosoc Nurs Ment Health Serv. 2013, 51:11-4. 10.3928\/02793695-20130513-01","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-002-0033-3","article-title":"Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone","volume":"19","author":"Belanoff JK","year":"2002","unstructured":"Belanoff JK, Jurik J, Schatzberg LD, DeBattista C, Schatzberg AF. Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone. J Mol Neurosci. 2002, 19:201-6. 10.1007\/s12031-002-0033-3","journal-title":"J Mol Neurosci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/110259-clinical-utility-of-mifepristone-apprising-the-expanding-horizons","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:48:51Z","timestamp":1707508131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/110259-clinical-utility-of-mifepristone-apprising-the-expanding-horizons"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,23]]},"references-count":93,"URL":"https:\/\/doi.org\/10.7759\/cureus.28318","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,23]]}}}